King of Prussia, PA, United States of America

Jeffrey K Kerns

USPTO Granted Patents = 17 (Patent Applications = 5)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 10 (Patent Applications = 14)

Average Co-Inventor Count = 3.8

ph-index = 3

Forward Citations = 48(Granted Patents)

Location History:

King of Prussia, PA (US) (2010 - 2021)
Collegeville, PA (US) (2023)

Company Filing History:

10 out of 230

Glaxosmithkline Intellectual Property Development Limited

patents

8 out of 123

Astex Therapeutics Limited

where one patent can have more than one assignee

Years Active: 2010-2024

Loading Chart...

17 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12091409 - Ether linked triazoles as NRF2 activators (2024-09-17),

2. 11643407 - Indanes as NRF2 activators (2023-05-09),

3. 11117905 - Bisaryl heterocycles as NRF2 activators (2021-09-14),

4. 11078216 - Bisaryl amides as NRF2 activators (2021-08-03),

5. 11059816 - Ether linked triazoles as NRF2 activators (2021-07-13),

6. 10604509 - Nrf2 regulators (2020-03-31),

7. 10485806 - Nrf2 regulators (2019-11-26),

8. 10364256 - Biaryl pyrazoles as NRF2 regulators (2019-07-30),

9. 10351530 - Arylcyclohexyl pyrazoles as NRF2 regulators (2019-07-16),

10. 10272095 - NRF2 regulators (2019-04-30),

11. 10144731 - Nrf2 regulators (2018-12-04),

12. 8501780 - Indazole carboxamides and their use (2013-08-06),

13. 8372875 - Indole carboxamides as IKK2 inhibitors (2013-02-12),

14. 8354406 - Chemical compounds (2013-01-15),

15. 8071584 - Indole carboxamides as IKK2 inhibitors (2011-12-06),

Title: Unveiling the Inventive Spirit of Jeffrey K Kerns

Introduction:

Meet Jeffrey K Kerns, a prolific inventor hailing from King of Prussia, PA in the United States. With an impressive portfolio of 16 patents to his name, Kerns is a true trailblazer in the realm of innovation.

Latest Patents:

Among his latest patents is the groundbreaking work on Indanes as NRF2 activators. This revolutionary invention encompasses indane compounds, their synthesis, pharmaceutical compositions featuring them, and their utilization as NRF2 activators. Kerns also made waves with his patent on Bisaryl heterocycles as NRF2 activators, showcasing his expertise in the field.

Career Highlights:

Kerns has lent his inventive genius to distinguished companies such as GlaxoSmithKline Intellectual Property Development Limited and Astex Therapeutics Limited. His contributions have not only shaped the pharmaceutical landscape but have also paved the way for significant advancements in the industry.

Collaborations:

Throughout his illustrious career, Kerns has collaborated with esteemed professionals like Thomas Daniel Heightman and James Francis Callahan. Together, they have spearheaded innovative projects, solidifying their positions as key players in the realm of patent development and pharmaceutical research.

Conclusion:

In conclusion, Jeffrey K Kerns stands as a beacon of innovation, with his remarkable patents and collaborative efforts underscoring his indelible mark on the field. His passion for pushing boundaries and creating transformative solutions continues to inspire and drive progress in the world of inventions.

This text is generated by artificial intelligence and may not be accurate.